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Abstract: The number of circulating tumor cells (CTCs) in blood is 
strongly correlated with the progress of metastatic cancer. Current 
methods to detect CTCs are based on immunostaining or 
discrimination of physical properties. Here, we present a label-free 
method exploiting the abnormal metabolic behaviour of cancer cells. 
We demonstrate a single-cell analysis technique to measure the 
secretion of acid of individual, living tumor cells compartmentalized 
in microfluidically prepared, monodisperse, pL droplets. We can 
detect as few as 10 tumor cells in a background of 200,000 white 
blood cells and show proof-of-concept data on the detection of CTCs 
in the blood of metastatic patients.  
Cancer is a generic term for a large group of diseases that can affect 
any part of the body. At some point during the development of most 
types of human cancer, primary tumor masses spawn pioneer cells that 
move out, invade adjacent tissues, and thence travel to distant sites 
where they may succeed in founding new colonies. A key step in the 
process of metastasis is the shedding of cells from primary tumors into 
the vasculature, which then circulate through the bloodstream and 
eventually re-penetrate vessel walls to form another tumor.[1] There is 
considerable evidence that these so-called circulating tumor cells 
(CTCs) are a key biomarker marking the progression of cancer 
metastasis and there is a direct correlation between survival times and 
number of CTCs in the peripheral blood.[1–6] A key limitation in the 
capture and analysis of CTCs is their extreme rarity relative to the 5 x 
109 erythrocytes and 1-10 x 106 leukocytes per mL of blood. Although 
red blood cells can be easily removed by osmotic cell lysis, leukocytes 
(white blood cells) share many of the physical chemical and biological 
properties of CTCs, leading to high contamination levels in many CTC 
detection methods.[7] Biochemical techniques for detecting and 
counting CTCs exploit the presence of surface and cytoplasmic 
proteins (epithelial cell adhesion molecule, EpCAM, or HER2, EGFR, 
MUC1, CKs) that are not present on leukocytes.[8] Currently, the only 
clinically validated method (CellSearch®)  is based on the enumeration 
of epithelial cells, which are separated from the blood by EpCAM-
coated magnetic beads and identified with the use of fluorescently 
labeled antibodies against cytokeratin (8, 18, 19) and with a fluorescent 
nuclear stain.[9] Although CellSearch® and other immunostaining-
based methods are able to detect EpCAM-positive CTCs reliably, not 
all CTCs may have epithelial surface markers due to a partial or 
complete epithelial-mesenchymal transition (EMT) that CTCs undergo 
when they escape from the primary tumor. As such, the EMT confers 
on epithelial cells precisely the set of traits that would empower them 
to disseminate from primary tumors and seed metastases.[10,11] 
Furthermore, Yu et al. have shown that the EMT is correlated to 
disease progression,[12] so these methods might be missing most 
relevant CTCs. There has been a large effort to develop alternative, 
low-cost, label-free techniques for the detection of CTCs based on 
physical properties such as the mechanical properties of CTCs, size 
selection, deformability, or electric charge. These techniques are 
reviewed elsewhere,[7] but the general conclusion is that although much 
promising progress has been made, the robustness in distinguishing 
between healthy cells and CTCs, and the isolation of live CTCs need to 
be improved further. We believe that cancer metabolism provides 
unique opportunities to achieve this requirement: an altered energy 
metabolism has been proven to be widespread in cancer cells and is 
one of hallmarks of cancer.[13,14,15-18] Otto Warburg first observed an 
anomalous characteristic of cancer cell metabolism in the 1920s:[19] 
even in the presence of oxygen, cancer cells limit their energy 
production largely to glycolysis, leading to massive secretion of lactate 
and acidification of the tumor environment, a phenomenon that has 
been termed the “Warburg effect” or “aerobic glycolysis”.[20] 
Acidification of the medium has been proven to be independent from 
Warburg effect, appearing early in tumorigenesis and increasing with 
the acquisition of more aggressive and metastatic phenotypes.[18] These 
metabolic alterations have been known for over 50 years, but they have 
never been used to detect CTCs, as such cells are so rare that they do 
not noticeably alter the pH levels or lactate concentration in a sample 
of blood. The key technological breakthrough presented here lies in 
splitting the macroscopic (blood) sample into small (picoliter-
nanoliter) aqueous droplets in oil (making a water-in-oil emulsion) 
using microfluidic technology[21]. Each droplet contains at most a 
single cell and all molecules secreted by this single cell are retained by 
the droplet.[22]  The pH range of cancer extracellular environment is 
known to be 6.2–6.9 compared with 7.3–7.4 of normal tissue, and 
secretion rate of lactic acid by tumor cells is in the range of 10-16 
mol/cell/sec, which is approx. 30-fold higher than the typical secretion 
rate of leukocytes.[23,24] Because of the small volume of the droplets, 
the concentrations of these secreted molecules rapidly increases up to 
measurable levels. CTCs are thus detected by pH measurements or 
lactate concentration changes in the extracellular compartment of 
individual cells, without the need for surface-antigen labelling (Figure 
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1A). To establish the validity of our approach, we emulsified a 
suspension of tumor cells from a cancer cell line (lung - A549) in 35 
pL droplets in the presence of culture medium and a lactic acid assay 
mixture (Sigma). The number of cells in each droplet followed a 
Poisson distribution ensuring >90% single cell encapsulation (NB, this 
means that most droplets will be empty; see Figure S1) and we 
demonstrated the production of lactate by A549 in drops (data not 
shown). We then mixed A549 cells with white blood cells (WBCs, 
Figure 1B), as these will be the primary background in blood samples 
taken from patients, and observed a clear ~ 2-fold intensity difference 
between droplets containing a cancer cell and empty or WBC 
containing drops (Figure 1C). There is some spread in the fluorescence, 
most likely due to a difference in lactate secretion rates between 
individual cells. Subsequently, in order to simplify the assay, we 
measured lactate secretion indirectly, by monitoring the pH of the 
droplet using a pH-sensitive dye (pHrodo Green) and obtained similar 
results (i.e. A549-containing droplets showed a clear drop in pH; see 
Figure S2). To screen droplets with higher throughput in a semi-
automated way, we engineered an inverted microscope (Figure 2), so 
that each droplet can be analyzed using laser-induced fluorescence at 
approximately 1 kHz.[25,26] We used a ratiometric dye (Snarf-5F, free 
carboxylic acid, Figure S3, S4) to increase the precision of the pH 
measurement. For each droplet the ratio of emitted fluorescence at 580 
and 630 nm is calculated in real time. In the presence of a cell secreting 
lactate the pH inside a droplet reduces below 7.4 and as a result an 
increase in 580/630 ratio above 1 is observed (Figure 2A). Real time 
analysis of each droplet enables us to capture images of a subset of 
droplets with increased 580/630 fluorescence ratios, thus providing an 
additional verification. The assay consists of three steps: a sample 
emulsification, incubation and a readout. To facilitate subsequent 
reinjection, droplets were generated, collected and incubated in a 
device with a cone-shaped chamber. After incubation all drops are 
injected in another device where each droplet is interrogated and 
fluorescence ratio is determined (see Figure S3 and S4 for calibration 
data). Using the developed method, we investigated secretion in 
various cancer cell lines. The secretion of lactate leads to a rapid 
increase in the concentration of acid in cell-containing droplets. Even 
after short incubation times (<2 minutes) a population of acidified 
droplets appears. This population increases further, approaching 
saturation after 10-20 minutes. Therefore, all our experiments were 
carried out using incubation times of at least 10 minutes (see Figure 
S5). To demonstrate that this is a general method for detection of 
cancer cells, we tested several other cancer cell lines, both EpCAM(+) 
and (-) including ovarian TOV21G, breast MDA-MB 453, 
glioblastoma U231, colorectal HT-29, breast MCF-7 and MDA-MB-
231 - and found that all show acidification of droplets (see Figure S6). 
We used the A549 cell line and WBC to simulate clinical samples and 
to investigate analytical figures of merit of the developed method. 
Experiments were then repeated using larger numbers of cells. Figure 
3A shows data points for 2M droplets of an emulsified A549 
suspension, and we see a clear fraction of cell-containing droplets with 
a reduced pH, against a large background of empty droplets of 
unchanged pH. Figures 3B shows data points for 2M droplets produced 
from a sample of WBCs from a healthy donor showing no acid-
positive droplets. Figure 3C shows data points for 2M droplets of the 
same sample with A549 cells spiked in, leading to a distinct population 
of acidified droplets. These figures clearly demonstrate that our method 
is capable of distinguishing healthy cells from metabolically active 
A549 (see Figure S9 for representative images). Figure S7 shows data 
on a similar experiment where all tumour cells were stained using 
Calcein Violet AM – a viability staining dye not affecting cell 
behaviour (cell viability during this assay was confirmed separately (se 
Figure S12) – prior to mixing. Most acid-positive droplets were also 
positive in the Calcein channel, confirming the excellent selectivity of 
the assay. We detected only rare acid-positive Calcein-negative drops, 
and by visualizing them we found out they were clusters of 10+ WBCs 
or junk artefacts.  
CTCs are extremely rare cells and the detection of these cells requires 
an assay with high sensitivity and specificity. To quantify both, we 
emulsified mixtures of A549 tumor cells with WBCs in ratios ranging 
from as few as 10:200,000 to 130:200,000 A549:WBC (total samples 
sizes containing 1M/mL WBCs). Figure 3D shows the number of 
tumor cells detected vs. number of tumor cells spiked in. Our method is 
capable of detecting A549’s even at the lowest dilutions tested, with 
average detection rates for all experiments in the range of 60%. We 
note that at low cell count, deviations between expected and recovered 
cell numbers might be due to variations in actual cells 
compartmentalized, and losses due to adhesion to tubing or syringe. 
Importantly, none of the low pH droplets contained WBCs (as 
confirmed by analysing the video images). With the method now 
firmly established, we tested samples based on blood of healthy donors 
as well as cancer patients with confirmed metastatic disease. To be able 
to process a large amount of blood, we depleted lysed blood of CD45+ 
cells (see SI). Prior to encapsulation, we stained WBC using a 
fluorescent antibody for CD45. Figures 4 and S10 clearly show that in 
the CD45(-) fraction no positive droplets are observed in samples 
derived from the blood of healthy volunteers, whereas numerous 
positive droplets are detected when either A549s are spiked into the 
healthy donor sample, or the sample of a metastatic colorectal cancer 
patient is analyzed. These positive droplets contain cells that acidify 
the microenvironment but are negative for CD45, providing a strong 
indication that these cells are most likely tumor cells. Further 
experiments on 4 other cancer patients (see Table S1) showed droplets 
that were acid positive/CD45-, and pictures of these droplets shows 
sometimes cells of comparable size to WBCs, sometimes of clearly 
different morphology compared to WBC (See Figure S11)). 
This work provides the first proof-of-concept indication that cancer 
cell metabolism, and more specifically, acidification of the 
extracellular microenvironment, can be used to identify and count rare 
tumor cells and CTCs. Further work is needed to confirm that these 
cells are indeed CTCs and if so, their cancer-specific proteins and 
genetic mutations must be profiled; to clarify how they can impact in 
clinical routine, positive events need to be isolated, while clinical 
parameters as sensitivity, specificity, predictive values, must be 
established by dedicated clinical trials.  
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An altered metabolism is one of 
cancer's hallmarks. Differences 
between healthy and cancerous cell 
metabolism, hidden in bulk, are 
apparent in tiny (pL) droplets 
containing individual cells. Within 
minutes cancerous cells generate a 
pH change in their 
microenvironment. By measuring 
the pH in each individual droplet 
CTC detection in patient samples is 
possible. 
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Figure 1. (A) CTC detection based on Warburg effect using compartmentalization in microdroplets. (B) 
A production of lactate by A549 cell in droplets. Only A549 containing droplets (large cells) show  
increase in fluorescence. Note that even with white blood cells clusters (smaller cells), drops do not 
show an increase in fluorescence. Pictures has been brightness/contrast enhanced. (C) A quantification 
of fluorescence in single drops based on raw pictures. 
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Figure 2. Detection of CTC using dual emission SNARF 5F dye. (A) Fragment of a raw data trace. Inset 
shows micrograph of a detected CTC. (B) Schematic of experimental setup. 
 
 
 
 
 
 
Figure 3. Detection of A549 cells. (A) Response of A549s alone in Joklik medium (pH 7.2). The dots 
with elevated ratio correspond to droplets with cancer cells. The majority of droplets don’t show 
significant change in ratio – these are empty droplets always present after emulsification. (B) Response 
of isolated WBC alone in the medium. (C) Mixture of A549 and WBCs in the medium. Open circles 
represent acidic droplets containing A549 cells. (D) The recovery of A549 cells spiked in. Solid 
diamonds represent recoveries observed with A549s only in the buffer and open diamonds represent 
A549s detected in the presence of WBC.  
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Figure 4. CTC detection in clinical samples. (A) Healthy volunteer sample. (B) Healthy volunteer 
sample with spiked tumor cells. (C) Sample from metastatic colorectal cancer patient. 
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